Insiders Trades
Tempus AI, Inc. Stock: price and insider trades · United States
Tempus AI, Inc.: what insiders have been doing
Headquartered in Chicago, Tempus AI, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Tempus AI, Inc. logged 178 filings by 27 insiders.
Only sales appear on the open market, 144 sales in all totalling €94.8M, filed by 11 insiders. No amount is published for 1 filing, which the totals therefore leave out. At €8.7M, the sale published on 18 September 2026 by Lefkofsky Eric P is the largest of the period (0.064% of market cap).
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 178 filings is above the norm. Our records for Tempus AI, Inc. go back to 2024, with no purchases and 230 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 1.27 bn USD and net income at -245.0 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
302
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€207M
230 ops. · all time
Who traded when
BuySaleEric P. Lefkofsky86 sales
Ryan Fukushima34 sales
Epstein David R12 sales
Polovin Andrew12 sales
Doudna Jennifer A10 sales
Rogers James William10 sales
+7 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Tempus AI, Inc. Buy (bullish), based on 18 analysts. Average price target: US$74.94.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,735 of 24,148 companies
29.5
score / 100
Value27
Quality32
FCF yld-2.1%
Earn yld-2.1%
EV/EBITDA·
ROE-67%
Gross mgn63%
Net mgn-19%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$64.72
Analyst consensus
18 analystsBuy
US$35.00Target US$74.94(+16%)US$100.00
Income statement
RevenueUS$1.3B
Gross profitUS$797.9M63% margin
EBITDA-US$118.5M-9% margin
Net income-US$245M-17.8% margin
Valuation
PER (forward)-1373.8x
P/Book26.2x
Beta3.54
Balance sheet & cash
Market capUS$11.7B
Total debtUS$1.3B
Free Cash Flow-US$245.4M
Debt / Equity325%
Profitability & ownership
ROE-67.4%
ROA-8.8%
% insiders36.8%
% institutions59.8%
Last declaration on 29 September 2026
Declarations302 total
10,281 shares@ US$85.000.0057% mcap44.3% of flowClass A Common StockSEC:0002113721-26-000018:0
10,281 shares@ US$82.240.0055% mcap68.3% of flowCommonSEC144:0001950047-26-009824
7,394 shares@ US$76.570.0037% mcap0.5% of flowClass A Common StockSEC:0001114357-26-000040:0
33,770 shares@ US$77.290.017% mcap2.3% of flowClass A Common StockSEC:0001114357-26-000040:1
16,152 shares@ US$78.230.0082% mcap1.1% of flowClass A Common StockSEC:0001114357-26-000040:2
184 shares@ US$78.860.0001% mcap0.0% of flowClass A Common StockSEC:0001114357-26-000040:3
17,359 shares@ US$76.570.0086% mcap1.2% of flowClass A Common StockSEC:0001114357-26-000040:4
79,259 shares@ US$77.290.040% mcap5.5% of flowClass A Common StockSEC:0001114357-26-000040:5
37,950 shares@ US$78.230.019% mcap2.7% of flowClass A Common StockSEC:0001114357-26-000040:6
432 shares@ US$78.860.0002% mcap0.0% of flowClass A Common StockSEC:0001114357-26-000040:7
965 shares@ US$76.570.0005% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000040:8
4,420 shares@ US$77.290.0022% mcap0.3% of flowClass A Common StockSEC:0001114357-26-000040:9
2,091 shares@ US$78.230.0011% mcap0.1% of flowClass A Common StockSEC:0001114357-26-000040:10
24 shares@ US$78.860.0000% mcap0.0% of flowClass A Common StockSEC:0001114357-26-000040:11
6,431 shares@ US$76.570.0032% mcap0.4% of flowClass A Common StockSEC:0001114357-26-000040:12
29,367 shares@ US$77.290.015% mcap2.0% of flowClass A Common StockSEC:0001114357-26-000040:13
14,042 shares@ US$78.230.0071% mcap1.0% of flowClass A Common StockSEC:0001114357-26-000040:14
160 shares@ US$78.860.0001% mcap0.0% of flowClass A Common StockSEC:0001114357-26-000040:15
250,000 shares@ US$78.030.13% mcap27.9% of flowClass A Common StockSEC144:0001968582-26-001001
123,391 shares@ US$80.520.064% mcap8.9% of flowClass A Common StockSEC:0001114357-26-000038:2
7,062 shares@ US$75.000.0034% mcap15.9% of flowClass A Common StockSEC:0001754464-26-000018:0
700 shares@ US$70.000.0003% mcap0.3% of flowClass A Common StockSEC:0002024250-26-000037:0
52,558 shares@ US$80.520.027% mcap3.8% of flowClass A Common StockSEC:0001114357-26-000038:0
4,942 shares@ US$81.090.0026% mcap0.4% of flowClass A Common StockSEC:0001114357-26-000038:1
11,609 shares@ US$81.090.0061% mcap0.8% of flowClass A Common StockSEC:0001114357-26-000038:3
25 of 302 declarations
About Tempus AI, Inc.
Tempus AI, Inc. is a U.S.-based healthcare technology company listed on the NASDAQ in the United States, operating at the intersection of artificial intelligence, genomics, and precision medicine. Founded in 2015 by Eric Lefkofsky in Chicago, the company was built around the idea that large-scale clinical and molecular data can materially improve treatment decisions, initially in oncology and increasingly across broader disease areas. Tempus is headquartered in Chicago, Illinois, and its commercial footprint is primarily U.S.-focused, serving hospitals, cancer centers, laboratories, researchers, and biopharma partners.
Tempus’ business model is built on complementary revenue streams. Its diagnostics segment offers molecular and genomic testing designed to better characterize tumors and other complex conditions. In parallel, the company commercializes data, analytics, and AI-powered tools that help users leverage proprietary clinical and molecular datasets for research, biomarker discovery, clinical trial matching, and decision support. This diagnostics-plus-data/software structure is a key differentiator versus traditional lab-testing companies and versus health-software vendors that lack Tempus’ owned data assets.
Read moreShow less
From a competitive standpoint, Tempus aims to become a leading precision-medicine platform. Its investment case rests on the scale and quality of its data, the integration between testing and software, and its ability to partner with pharmaceutical companies, academic institutions, and health systems. The company has also been emphasizing new AI-enabled products and strategic partnerships to strengthen its position in patient stratification, screening, and care optimization.
Recent milestones underscore the company’s momentum. On May 5, 2026, Tempus reported first-quarter 2026 revenue of $348.1 million, up 36.1% year over year, and it highlighted multiple collaborations, including initiatives with Bristol Myers Squibb and USC. In early May 2026, Tempus also announced a $400 million convertible senior notes offering intended to optimize its capital structure and reduce interest expense. In addition, the company was named by TIME as one of the 10 Most Influential Health and Life Science Companies of 2026. For investors, Tempus remains a high-growth healthcare technology name with meaningful upside tied to data monetization and product adoption, but also with the usual execution, reimbursement, regulatory, and commercialization risks inherent in precision medicine.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
